Filing Flows › UroGen Pharma (URGN) › R&D spending
UroGen Pharma (URGN) R&D spending by quarter
UroGen Pharma's R&D spending was $26.0M in Q3 2026 (third quarter 2026), +50% from Q2 2026. Over the last 7 quarters it ranged from $14.0M (Q3 2025) to $26.0M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $26.0M | +50% | +85% |
| Q2 2026 | $17.3M | +11% | -8% |
| Q1 2026 | $15.6M | +9% | -22% |
| Q4 2025 | $14.3M | +2% | — |
| Q3 2025 | $14.0M | -26% | — |
| Q2 2025 | $18.9M | -5% | — |
| Q1 2025 | $19.9M | — | — |
Q3 2026 at a glance
UroGen Pharma, Q3 2026: revenue $89.0M (+224% year over year), operating margin 9.4%, net loss $1.5M, operating cash flow −$15.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is UroGen Pharma's R&D spending?
UroGen Pharma's R&D spending was $26.0M in Q3 2026 (third quarter 2026), +50% from Q2 2026.
How has UroGen Pharma's R&D spending changed?
Over the last 7 quarters it ranged from $14.0M (Q3 2025) to $26.0M (Q3 2026).